Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs

BMC Veterinary Research

Table 3 Comparison of percent of cells positive for CD11b/CADO48A by gate amongst tumor types

Sarcoma	Mean	Median	Min	Max
Ungated	33.4±12.7	28.7	13.5	58.2
R1	29.9±12.5*	26.5	11.7	53.1
P1	29.0±12.6*	25.5	11.6	51.8
P2	25.1±12.0	22.4	8.2	50.6
P3	4.8±4.7	3.5	1.6	20.3
P4	4.7±2.9	3.8	1.1	12.6
*Carcinoma*
Ungated	30.4±14.8	23.8	11.4	64.5
R1	26.4±12.8*	21.5	8.5	55.6
P1	25.3±12.5*	21.0	7.2	53.6
P2	22.7±11.4	18.2	8.1	47.9
P3	3.7±1.9	3.1	1.2	8.0
P4	5.1±3.5	3.5	2.1	12.7
*Melanoma*
Ungated	56.0±15.2	53.5	42.3	72.3
R1	52.6±13.5*	51.0	40.0	66.9
P1	51.6±13.0*	50.2	39.3	65.2
P2	44.7±13.5	41.2	33.3	59.6
P3	7.8±2.2	7.7	5.7	10.1
P4	4.8±1.1	4.5	3.8	6.0

The percentage of cells staining positive for CD11b and CADO48A are displayed for each tumor subtype: sarcoma (n= 19), carcinoma (n=18) and melanoma (n=3). Patients were categorized into one of the three groups based on either cytology or histopathology. A statistical difference was seen in the R1 and P1 gates between the 3 tumor types on initial analysis. When the melanoma patients were excluded due to low patient numbers no statistical difference was seen in the percent of CD11b/CADO48A positive cells, in any gate, between the sarcoma or carcinoma patients. An * denoted statistical significance (p<0.05). All values are expressed as a percentage of all cells analyzed by flow cytometry.

ISSN: 1746-6148